Published in Cancer Weekly, March 5th, 2002
De Novo and SUN will pool their resources to codevelop a comprehensive chemoinformatics platform to house designs of potential drugs produced by De Novo's proprietary software. De Novo and SUN will each supply expertise necessary for the creation of this new technology platform, based on De Novo's existing de novo structure-generator, Skelgen and SUN's high-performance computing platforms.
De Novo's initial investment with Sun comprises a fully integrated, scalable 80-node compute...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.